A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors

Male and female subjects ≥ 16 years of age with a diagnosis of EFT or DSRCT who have relapsed or progressed after at least one prior chemotherapeutic regimen will be eligible for this study. Before any study-specific procedure, the appropriate written informed consent must be obtained. Inclusion Criteria: Disease Related Subjects with pathological or histological diagnosis of Ewing’s Family Tumor or Desmoplastic Small Round Cell Tumor. • Measurable disease as defined by RECIST. • Documented failure of at least one prior chemotherapy regimen for their disease. • Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2. Demographic • Males or females ≥ 16 years old. • Signed written informed consent. • Able to comply with visits and procedures. Laboratory • Willing to provide existing and/or newly acquired tumor samples. • Diabetic Subjects (Type 1 or 2) must have HgbA1c < 8.0% and fasting blood glucose level < 160 mg/dL. General • Must be willing and able to use birth control (double barrier protection or abstinence) during and for 6 months after the study • Prior exposure to another anti-IGF-1R therapy will only be allowed for a limited number of additional subjects (up to 10) in an exploratory cohort Exclusion Criteria Disease Related • Known brain metastasis. • History of bleeding diathesis. • History of another malignancy. • History of chronic hepatitis. • Documented prior history of human immunodeficiency virus. Laboratory • Absolute neutrophil count < 1.5 x109/L. • Platelet count < 100 x 109/L. • Hemoglobin < 9 g/dL. • PT > 1.5 x institutional upper limit of normal (IULN) or PTT > 1.0 x IULN. • Serum creatinine > 1.5 x IULN. • Aspartate aminotransferase (AST) > 2.5 x IULN or Alanine aminotransferase (ALT) > 2.5 x IULN (> 5.0 x if liver metastases present). • Total bilirubin > 1.5 IULN (> 3.0 x with documented Gilbert’s Syndrome) Medication • Antitumor treatment within 21 days of Study Day 1. • Anticoagulation therapy within 28 days of Study Day 1. • Major surgery within 28 days of Study Day 1. General • Other investigational procedures are excluded. • Inability to tolerate intravenous administration. • Subject is pregnant (eg, positive HCG test) or is breast feeding.